TY - JOUR
T1 - Effect of antimicrobial stewardship with rapid MALDI-TOF identification and Vitek 2 antimicrobial susceptibility testing on hospitalization outcome
AU - Cavalieri, Stephen J.
AU - Kwon, Seunghyug
AU - Vivekanandan, Renuga
AU - Ased, Sumaya
AU - Carroll, Cassara
AU - Anthone, Jennifer
AU - Schmidt, David
AU - Baysden, Maddy
AU - Destache, Christopher J.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - We sought to evaluate time for bacterial culture and initiation of appropriate therapy for patients, from 2017 (without rapid diagnostic test (RDT) and Antimicrobial Stewardship Program (ASP)) and 2018 (with RDT and ASP). Time to identification (ID) was significantly faster in 2018 (2018 24.9 ± 14.4, 2017 33.8 ± 17 h, P = 0.001). Time to antimicrobial susceptibility test (AST) results was significantly faster for patients in 2018 compared to 2017 (18.2 ± 14 h compared to 28.5 ± 14.9 h, P < 0.001). Length of hospital stay for enrolled patients was significantly shorter in 2018 compared to 2017 (2018 10.7 ± 11.1 days and 2017 15.5 ± 18.1 days, P = 0.05). Length of antimicrobial therapy for enrolled patients was significantly shorter for 2018 (2018 6.7 ± 3.8 d vs. 2017 8.8 ± 7.8 d, P = 0.036). These results demonstrate MALDI-TOF/Vitek 2 leads to an average 21.5 h faster ID and AST results that can be acted upon by ASP for antimicrobial recommendations.
AB - We sought to evaluate time for bacterial culture and initiation of appropriate therapy for patients, from 2017 (without rapid diagnostic test (RDT) and Antimicrobial Stewardship Program (ASP)) and 2018 (with RDT and ASP). Time to identification (ID) was significantly faster in 2018 (2018 24.9 ± 14.4, 2017 33.8 ± 17 h, P = 0.001). Time to antimicrobial susceptibility test (AST) results was significantly faster for patients in 2018 compared to 2017 (18.2 ± 14 h compared to 28.5 ± 14.9 h, P < 0.001). Length of hospital stay for enrolled patients was significantly shorter in 2018 compared to 2017 (2018 10.7 ± 11.1 days and 2017 15.5 ± 18.1 days, P = 0.05). Length of antimicrobial therapy for enrolled patients was significantly shorter for 2018 (2018 6.7 ± 3.8 d vs. 2017 8.8 ± 7.8 d, P = 0.036). These results demonstrate MALDI-TOF/Vitek 2 leads to an average 21.5 h faster ID and AST results that can be acted upon by ASP for antimicrobial recommendations.
UR - http://www.scopus.com/inward/record.url?scp=85068268847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068268847&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2019.05.020
DO - 10.1016/j.diagmicrobio.2019.05.020
M3 - Article
C2 - 31279585
AN - SCOPUS:85068268847
SN - 0732-8893
VL - 95
SP - 208
EP - 211
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -